#United States #Denver #Citius Oncology #LYMPHIR™ #USCLC Workshop

Citius Oncology to Present at USCLC Annual Workshop 2026

Citius Oncology, Inc. (Nasdaq: CTOR), a biopharmaceutical company focused on oncology, will actively engage at the upcoming USCLC Annual Workshop 2026, scheduled for March 26, 2026, in Denver, Colorado. This event is a pivotal platform where leading experts from dermatology and oncology converge to discuss advancements in cutaneous lymphomas, especially cutaneous T-cell lymphoma (CTCL).

About the Workshop

The USCLC Annual Workshop is recognized as a premier scientific meeting dedicated to cutaneous lymphomas. This year, the workshop's theme, "Frontiers in Cutaneous Lymphoma New Technologies, Therapeutics, and Future Directions," will feature sessions that delve into novel diagnostics, radiological advancements, emerging therapies, and the future direction of research in this area. The format emphasizes direct interactions among experts, enabling the sharing of insights and best practices regarding treatment paradigms and clinical experiences.

Citius Oncology's participation highlights its commitment to engaging with the clinical community treating patients suffering from CTCL. The workshop will facilitate one-on-one discussions where Citius will share insights on their recent FDA-approved therapy, LYMPHIR™ (denileukin diftitox-cxdl), and gather valuable feedback from clinicians and researchers based on their treatment experiences.

Insights from Citius Oncology

Leonard Mazur, the Chairman and CEO of Citius Pharmaceuticals, expressed enthusiasm about engaging with leading CTCL clinicians at this workshop. He acknowledged the USCLC as a hub for many experts in CTCL care, emphasizing the importance of these discussions for advancing treatment strategies and improving patient outcomes.

LYMPHIR™ is a groundbreaking targeted immune therapy specifically indicated for adult patients with relapsed or refractory CTCL, representing a significant advancement in the treatment landscape. Its mechanism targets IL-2 receptors on tumor cells, combining this with diphtheria toxin fragments to induce apoptosis in malignant cells.

In December 2025, LYMPHIR™ was launched in the U.S. after receiving FDA approval, establishing a competitive position for Citius Oncology in a market estimated to exceed $400 million and continue growing. The firm’s focus on robust intellectual property protections surrounds LYMPHIR™, further solidifying its potential impact in oncology.

The Importance of Collaboration

The USCLC promotes collaborative efforts among various specialties including dermatology, medical oncology, radiation oncology, and pathology. This is crucial for breaking down communication barriers and fostering innovative approaches to the treatment and research of cutaneous lymphomas. Key initiatives such as a national registry and clinical trials network emphasize their commitment to improving patient care through research.

At the workshop, Citius Oncology's team will engage closely with investigators and thought leaders, contributing to a shared understanding of the therapeutic landscape and exploring opportunities for enhanced patient care. They aim to gather insights that can directly influence their strategies in deploying LYMPHIR™ effectively.

Conclusion

As Citius Oncology prepares to share their innovations and hear from leading voices in the field, the USCLC Annual Workshop 2026 promises to be a pivotal event for the ongoing advancement in the treatment of CTCL. Through collaboration and dialogue, they aim to continue refining approaches that will improve patient outcomes in this challenging disease landscape. Stay tuned for further developments as Citius Oncology continues its mission to revolutionize treatments for cutaneous lymphomas and support the medical community dedicated to this cause.